Financial Performance - First quarter 2025 net sales were $0.8 million, a decrease from $3.6 million in the prior year period, attributed to order timing for PHEXXI[4] - Total operating expenses in Q1 2025 were $0.5 million, significantly lower than $6.4 million in the same period last year[5] - Evofem recorded income from operations of $0.3 million in Q1 2025, compared to a loss of $2.8 million in Q1 2024[7] - Net income attributable to common stockholders was $1.0 million in Q1 2025, a turnaround from a net loss of $4.9 million in Q1 2024, resulting in net income of $0.01 per basic share[7] Cash and Funding - Cash, cash equivalents, and restricted cash totaled $1.1 million as of March 31, 2025, up from $0.7 million at the end of 2024[8] - Evofem raised $1.5 million in April 2025 from the sale of senior subordinated notes and warrants[6] Cost Management and Development - Evofem aims to reduce PHEXXI manufacturing costs by 55% to 60% through a partnership with Windtree Therapeutics, Inc.[6] - Research and development expenses decreased by $5.6 million due to successful negotiations with vendors, with a 4% reduction excluding settlements compared to the prior year[11] Product Launch and Market Expansion - The commercial team relaunched SOLOSEC in November 2024 and is entering global markets, including a planned launch of PHEXXI in the UAE in early 2026[10] - The company strengthened its intellectual property with the issuance of an 11th U.S. patent for SOLOSEC, extending coverage to 2040[6]
EVOFEM BIOSCIENC(EVFM) - 2025 Q1 - Quarterly Results